U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H18ClN3O5S
Molecular Weight 435.881
Optical Activity ( - )
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RIVAROXABAN

SMILES

ClC1=CC=C(S1)C(=O)NC[C@H]2CN(C(=O)O2)C3=CC=C(C=C3)N4CCOCC4=O

InChI

InChIKey=KGFYHTZWPPHNLQ-AWEZNQCLSA-N
InChI=1S/C19H18ClN3O5S/c20-16-6-5-15(29-16)18(25)21-9-14-10-23(19(26)28-14)13-3-1-12(2-4-13)22-7-8-27-11-17(22)24/h1-6,14H,7-11H2,(H,21,25)/t14-/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including http://www.biospace.com/News/bayer-healthcares-xarelto-rivaroxaban-becomes/244131

Rivaroxaban (trade name Xarelto) is an oral anticoagulant. It is the first available orally active direct factor Xa inhibitor. Upon oral administration, rivaroxaban selectively binds to both free factor Xa and factor Xa bound in the prothrombinase complex. This interferes with the conversion of prothrombin (factor II) to thrombin and eventually prevents the formation of cross-linked fibrin clots. Rivaroxaban does not affect existing thrombin levels. Activation of factor X to factor Xa (FXa) via the intrinsic and extrinsic pathways plays a central role in the cascade of blood coagulation. Xarelto is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, treatment and prophylaxis of deep vein thrombosis (DVT) which may lead to PE in patients undergoing knee or hip replacement surgery, pulmonary embolism (PE) and for the reduction in the risk of recurrence of deep vein thrombosis and of pulmonary embolism following initial 6 months treatment for DVT and/or PE.

CNS Activity

CNS Non-penetrant
1050
Curator's Comment: Rivaroxaban is distributed heterogeneously to tissues and organs, exhibiting only moderate tissue affinity and does not substantially penetrate the blood-brain barrier.

Originator

Bayer
178
Curator's Comment: Rivaroxaban was discovered in Bayer HealthCare Pharmaceuticals' Wuppertal laboratories in Germany, and is being jointly developed by Bayer HealthCare and Johnson & Johnson Pharmaceutical. # Bayer HealthCare Pharmaceuticals

Approval Year

2011
562
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8228
 0.4 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Secondary
Approved
8360
XARELTO

Approved Use

Indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, for the treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and for the reduction in the risk of recurrence of DVT and of PE for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery.

Launch Date

1.30947835E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
138.4 μg/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/23999929/
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIVAROXABAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1.114 μg × h/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/23999929/
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIVAROXABAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
10.77 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/23999929/
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIVAROXABAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
9 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202439s031,022406s035lbl.pdf
20 mg 1 times / day unknown, oral
dose: 20 mg
route of administration: Oral
experiment type: UNKNOWN
co-administered:
RIVAROXABAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
5%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202439s031,022406s035lbl.pdf
20 mg 1 times / day unknown, oral
dose: 20 mg
route of administration: Oral
experiment type: UNKNOWN
co-administered:
RIVAROXABAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
80 mg single, oral
Highest studied dose
Dose: 80 mg
Route: oral
Route: single
Dose: 80 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/16198660
Page: p.419
healthy, 19-45
n = 6
Health Status: healthy
Age Group: 19-45
Sex: M
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/16198660
Page: p.419
Sources:
https://pubmed.ncbi.nlm.nih.gov/16198660
Page: p.419
50 mg single, oral
Studied dose
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/18715524
Page: p.2759, p.2760
healthy, 60-76
n = 12
Health Status: healthy
Age Group: 60-76
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/18715524
Page: p.2759, p.2760
Sources:
https://pubmed.ncbi.nlm.nih.gov/18715524
Page: p.2759, p.2760
20 mg 1 times / day multiple, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Page: p.1, p.12
unhealthy
n = 7111
Health Status: unhealthy
Condition: Atrial Fibrillation
Sex: M+F
Population Size: 7111
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Page: p.1, p.12
Disc. AE: Bleeding...
AEs leading to
discontinuation/dose reduction:
Bleeding (grade 3-5, 4.3%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Page: p.1, p.12
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Page: p.1, p.14
unhealthy
Health Status: unhealthy
Condition: Deep Vein Thrombosis|Pulmonary Embolism
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Page: p.1, p.14
Disc. AE: Bleeding...
AEs leading to
discontinuation/dose reduction:
Bleeding (2%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Page: p.1, p.14
20 mg 1 times / day multiple, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Atrial Fibrillation|Deep Vein Thrombosis|
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Page: p.1
Disc. AE: Spinal epidural hematoma...
AEs leading to
discontinuation/dose reduction:
Spinal epidural hematoma
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Page: p.1
20 mg 2 times / day multiple, oral (max)
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Page: p.1, p.14
unhealthy
n = 4130
Health Status: unhealthy
Condition: Deep Vein Thrombosis|Pulmonary Embolism
Sex: M+F
Population Size: 4130
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Page: p.1, p.14
Disc. AE: Bleeding...
AEs leading to
discontinuation/dose reduction:
Bleeding (1.7%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Page: p.1, p.14
AEs

AEs

AESignificanceDosePopulation
Bleeding grade 3-5, 4.3%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Page: p.1, p.12
unhealthy
n = 7111
Health Status: unhealthy
Condition: Atrial Fibrillation
Sex: M+F
Population Size: 7111
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Page: p.1, p.12
Bleeding 2%
Disc. AE
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Page: p.1, p.14
unhealthy
Health Status: unhealthy
Condition: Deep Vein Thrombosis|Pulmonary Embolism
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Page: p.1, p.14
Spinal epidural hematoma Disc. AE
20 mg 1 times / day multiple, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Atrial Fibrillation|Deep Vein Thrombosis|
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Page: p.1
Bleeding 1.7%
Disc. AE
20 mg 2 times / day multiple, oral (max)
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Page: p.1, p.14
unhealthy
n = 4130
Health Status: unhealthy
Condition: Deep Vein Thrombosis|Pulmonary Embolism
Sex: M+F
Population Size: 4130
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
Page: p.1, p.14
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1579

inducer
768
inhibitor
1752
inhibitor
1837
inhibitor
1599

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1509

CYP2C8
901

CYP2C19
1463

CYP2J2
16

P-gp
1437

BCRP
691
CYP3A4/5
85

CYP2J2
56

P-gp
1527

BCRP
555
CYP1A2
689

CYP2B6
538

CYP2C19
290
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
BCRP
765
 no
CYP1A2
1673
 no
CYP1A2
1673
 no
CYP2B6
985
 no
CYP2C19
1537
 no
CYP2C19
1537
 no
CYP2C8
955
 no
CYP2C9
1803
 no
CYP2D6
1875
 no
CYP2J2
19
 no
CYP3A4
1909
 no
CYP3A4
1909
 no
P-gp
1626
 no
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
BCRP
555
 yes
CYP2J2
56
 yes
CYP3A4/5
85
 yes
yes (co-administration study)
Comment: ketoconazole increased cmax of rivaroxaban 0.7x, auc 1.6x
Page: 9.0
P-gp
1527
 yes
yes (co-administration study)
Comment: ketoconazole increased cmax of rivaroxaban 0.7x, auc 1.6x
Page: 9.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1632
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:68579
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:68579
ChemicalBook
CB91176772
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB91176772
MolPort
MolPort-003-850-195
https://www.molport.com/shop/molecule-link/MolPort-003-850-195
ZINC
ZINC000003964126
http://zinc15.docking.org/substances/ZINC000003964126
eMolecules
27523812
https://www.emolecules.com/cgi-bin/more?vid=27523812
PubMed

PubMed

TitleDatePubMed
In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor.
2005 Mar
Pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--in rats and dogs.
2005 Sep
[Haemostasis and antithrombotic drugs: pharmacology and novel therapeutic approaches].
2006 May
The scientific community's quest to identify optimal targets for anticoagulant pharmacotherapy.
2006 Nov 28
A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.
2006 Nov 28
Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement.
2007
Gateways to clinical trials.
2007 Apr
In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban.
2007 Apr
Investigational treatments of venous thromboembolism.
2007 Apr
Anithrombotic prevention in vascular disease: bases for a new strategy in antithrombotic therapy.
2007 Aug 29
Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects.
2007 Feb
Ultrasound screening for asymptomatic deep vein thrombosis after major orthopaedic surgery: the VENUS study.
2007 Jul
A replacement for warfarin: the search continues.
2007 Jul 10
Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies.
2007 Jun
Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases.
2007 Jun
Gateways to clinical trials.
2007 Mar
Drug evaluation: rivaroxaban, an oral, direct inhibitor of activated factor X.
2007 Mar
[New antitoagulants].
2007 Mar
Rivaroxaban.
2007 Mar
Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
2007 Mar
Rivaroxaban. A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders.
2007 Sep
Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery.
2008
Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation.
2008
Gateways to clinical trials.
2008 Apr
[Perioperative venous thromboembolism prophylaxis: short review and recommendations].
2008 Dec
[Rivaroxaban: clinical pharmacology].
2008 Dec
The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update.
2008 Feb
Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa.
2008 Feb
Update on atrial fibrillation: part I.
2008 Feb
New oral anticoagulants in atrial fibrillation.
2008 Jan
Gateways to clinical trials.
2008 Jan-Feb
Selective factor Xa inhibition for thromboprophylaxis.
2008 Jul 5
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.
2008 Jul 5
Gateways to clinical trials.
2008 Jun
Rivaroxaban, an oral direct factor Xa inhibitor.
2008 Jun
Potent anticoagulants are associated with a higher all-cause mortality rate after hip and knee arthroplasty.
2008 Mar
[New oral anticoagulants: molecular characteristics, mechanisms of action, pharmacokinetics and pharmacodynamics].
2008 Nov
[Rivaroxaban. The first factor Xa inhibitor].
2008 Nov
Thromboprophylaxis with rivaroxaban or enoxaparin did not differ for major bleeding in knee arthroplasty.
2008 Nov-Dec
Orally administered factor xa inhibitor, rivaroxaban: a novel thromboembolic prophylaxis agent.
2008 Oct
[Always more amputations in Germany?].
2008 Oct
More effective, simpler-to-use clot-buster is on the way. Clot-prevention drug could save lives after joint replacement.
2008 Oct
Rivaroxaban: future in anticoagulation practice?
2008 Oct
Polyphosphate as a general procoagulant agent.
2008 Oct
New developments in anticoagulation for atrial fibrillation.
2008 Sep
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study.
2008 Sep 15
Rivaroxaban: a novel, oral, direct factor Xa inhibitor.
2009 Feb
Patents

Patents

07351823
1
08101601
1
08106192
1
08334284
1
08362015
2
08648189
1
20030153610
1
20040242660
1
JP2006513227A
1
JP2007517816A
1
JP2010505534A
1
JP2010539945A
2
JP2011502514A
8
JP2011502515A
8
JP2011510067A
55
JP2011526266A
1
JP4667044B2
1
JP5311742B2
1
JP5352461B2
1

Sample Use Guides

In Vivo Use Guide
15 mg and 20 mg tablets with food; take 10 mg tablets with or without food. For patients with CrCl >50 mL/min 20 mg orally, once daily and for patients with CrCl 15 - 50 mL/min 15 mg orally, once daily with the evening meal.
Route of Administration: Oral
In Vitro Use Guide
To evaluate the influence of prothrombin complex concentrate (PCC) on the anticoagulant effects of rivaroxaban as measured by prothrombin time (PT) and thrombin generation tests plasma and whole blood samples from healthy volunteers were spiked with Rivaroxaban (up to 800 ug/L) and prothrombin complex concentrate (PCC) was added to these samples in concentration ranges as used clinically to reverse the effects of vitamin K antagonists. Prothrombin complex concentrate does not neutralize the lengthening effect on PT and TGT lag time/T-Lag of rivaroxaban anticoagulated blood in vitro; however, total thrombin potential could be normalized.
Name Type Language
RIVAROXABAN
DASH   EMA EPAR   INN   JAN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
Rivaroxaban [WHO-DD]
Common Name English
RIVAROXABAN [EMA EPAR]
Common Name English
JNJ-39039039
Code English
RIVAROXABAN [ORANGE BOOK]
Common Name English
RIVAROXABAN [MI]
Common Name English
RIVAROXABAN [USP-RS]
Common Name English
rivaroxaban [INN]
Common Name English
RIVAROXABAN [MART.]
Common Name English
2-THIOPHENECARBOXAMIDE, 5-CHLORO-N-(((5S)-2-OXO-3-(4-(3-OXO-4-MORPHOLINYL)PHENYL)-5-OXAZOLIDINYL)METHYL)-
Systematic Name English
RIVAROXABAN [VANDF]
Common Name English
JNJ39039039
Code English
RIVAROXABAN [JAN]
Common Name English
BAY 59-7939
Code English
RIVAROXABAN [USAN]
Common Name English
RIVAROXABAN [EP MONOGRAPH]
Common Name English
XARELTO
Brand Name English
5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide
Systematic Name English
BAY-59-7939
Code English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS XARELTO (AUTHORIZED: ARTHROPLASTY, REPLACEMENT)
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
NCI_THESAURUS C263
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
WHO-ATC B01AF01
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
NDF-RT N0000175637
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
EMA ASSESSMENT REPORTS XARELTO (AUTHORIZED: VENOUS THROMBOEMBOLISM)
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
WHO-ATC B01AX06
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
WHO-VATC QB01AF01
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
LIVERTOX NBK548015
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
LOINC 74871-5
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
Code System Code Type Description
EPA CompTox
DTXSID3057723
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
PRIMARY
NCI_THESAURUS
C77995
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
PRIMARY
DRUG BANK
DB06228
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
PRIMARY
MERCK INDEX
M9638
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
PRIMARY Merck Index
DAILYMED
9NDF7JZ4M3
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
PRIMARY
WIKIPEDIA
RIVAROXABAN
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
PRIMARY
FDA UNII
9NDF7JZ4M3
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
PRIMARY
INN
8428
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
PRIMARY
IUPHAR
6388
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
PRIMARY
USAN
SS-99
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
PRIMARY
ChEMBL
CHEMBL198362
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
PRIMARY
RXCUI
1114195
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
PRIMARY RxNorm
CAS
366789-02-8
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
PRIMARY
DRUG CENTRAL
4182
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
PRIMARY
MESH
C503223
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
PRIMARY
PUBCHEM
9875401
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
PRIMARY
SMS_ID
100000092811
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
PRIMARY
LACTMED
Rivaroxaban
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
PRIMARY
RS_ITEM_NUM
1604530
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
PRIMARY
HSDB
8149
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
PRIMARY
EVMPD
SUB29263
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
PRIMARY
CHEBI
68579
Created by admin on Wed Jul 05 23:20:55 UTC 2023 , Edited by admin on Wed Jul 05 23:20:55 UTC 2023
PRIMARY
ACTIVE MOIETY
Structure of RIVAROXABAN
METABOLITE (PARENT)
Structure of RIVAROXABAN DIOL
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966